HIV

The AJMC^® HIV compendium is a comprehensive resource for clinical news and expert insights for the condition, including disparities in care, prevention of infection among at-risk groups, and the importance of viral suppression.

Latest News

PrEP | Image credit: Pepermpron - stock.adobe.com

Most Patients With HIV Opted for Injectable ART, PrEP in Phase 3 Trial

By Julia Bonavitacola

July 16th 2025

New data demonstrated that long-acting cabotegravir was preferable to daily dolutegravir/lamivudine in treatment-naive people living with HIV.

Doctor comforting patient | Image credit: H_Ko - stock.adobe.com

Use of Depression Services Differed by Demographics in People Living With HIV

By Julia Bonavitacola

July 10th 2025

Doctors with red ribbon | Image credit: michaeljung - stock.adobe.com

End of PEPFAR Funding Could Lead to Tens of Thousands of HIV Deaths

By Julia Bonavitacola

July 8th 2025

Black man with HIV | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com

Preference for Long-Acting vs On-Demand PrEP Seen in Black Men in the US

By Julia Bonavitacola

July 3rd 2025

PrEP | Image credit: alimyakubov - stock.adobe.com

Higher Levels of PrEP Use Associated With Reduction in HIV Diagnoses

By Julia Bonavitacola

June 30th 2025

Clarifying USPSTF Recommendations for HIV Pre-Exposure Prophylaxis (PrEP)

This discussion focuses on how to address barriers and disparities as obstacles to using PrEP, with a focus on USPSTF PrEP guidelines and ACA Part 47 for payers and providers.

This multi-stakeholder roundtable panel discussion will focus on how to address barriers and disparities as obstacles to the use of PrEP, with a focus on increased understanding and education around US Preventive Services Task Force (USPSTF) PrEP guidelines and Affordable Care Act Part 47 for payers and providers.

Continuing Medical Education

July 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Opioid Use Has a Detrimental Effect on Uptake of Care for Uncontrolled HIV

June 24th 2020

Opioid Use Has a Detrimental Effect on Uptake of Care for Uncontrolled HIV

Individuals who self-report a problem with drugs, especially opioids, are more likely to have uncontrolled HIV, to not be adherent to antiretroviral therapy, and to engage less in primary care for their infection but more in risky behaviors, including sharing needles and having multiple concurrent sexual partners.

Fauci: Countless Lives Have Been Saved, but an HIV Vaccine and Cure Remain Elusive

June 21st 2020

Fauci: Countless Lives Have Been Saved, but an HIV Vaccine and Cure Remain Elusive

To mark the 25th anniversary of The American Journal of Managed Care®, we spoke with Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID). Fauci has been at NIAID for 36 years, and he gave a keynote address at the 6th International AIDS Conference in San Francisco in 1990. Here he speaks on progress that has been made in the fight against HIV and AIDS, from AZT to Truvada to undetectable viral loads; why there is no cure just yet; and how the first tumultuous years of the AIDS crisis shaped research for decades to come.

June 19th 2020

From the Editor-in-Chief: Bigger Questions of Systems, Viruses, and the Lives of Real People

Joseph Alvarnas, MD

As I recall the early days of the HIV/AIDS pandemic, what stands out most is its profound human cost and the courage of those who helped our society transcend it. We are in the midst of a time in which the human toll of COVID-19 and the enormity of the path ahead are clear.

June 19th 2020

References for Humility and Hope, Alvarnas

Joseph Alvarnas, MD

References: Humility and Hope: Evolution of the HIV Pandemic, From ART to Today’s Cancer Cures

June 19th 2020

Humility and Hope: Evolution of the HIV Pandemic, From ART to Today's Cancer Cures

Joseph Alvarnas, MD

The connections between cancer and HIV/AIDS became clear relatively early in the HIV/AIDS pandemic and continue to this day. Not only were opportunistic infections present in a majority of HIV-infected patients who met the initial diagnostic criteria for AIDS, but several cancer types were far more prevalent as well. While there is still much to understand before HIV is fully conquered, we have already learned a great deal about the pathobiology of this virus that has helped advanced immune-oncological technologies and led to the development of increasingly effective gene therapy delivery systems.

June 18th 2020

Challenges and Similarities in HIV, COVID-19 Crises: A Q&A With Anthony Fauci, MD

Allison Inserro

To mark the 25th anniversary of The American Journal of Managed Care®, each issue in 2020 will include a special feature: an interview with a thought leader in the world of health care and medicine. The July issue features a conversation with Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

Having a High Risk of HCV Does Not Always Lead to Testing Among Those With HIV

June 18th 2020

Having a High Risk of HCV Does Not Always Lead to Testing Among Those With HIV

Despite the CDC’s recommendation, which has been in effect since 1998, study results show that just half of HIV-positive individuals choose to get tested for hepatitis C virus (HCV) in the 12 months following the receipt of their diagnosis.

June 17th 2020

Zaia Draws on Decades of Innovation in Infectious Disease for Breakthroughs in Gene Therapy

Known as a gene therapy pioneer, Zaia has spent almost 40 years at City of Hope, in Duarte, California. He was first drawn by the promise of studying cytomegalovirus. Over the decades, his groundbreaking research has encompassed HIV/AIDS, cellular gene transfer therapy, immunotherapy, bispecific antibodies, and now hyperimmune globulin for workers on the frontlines of the coronavirus disease 2019 (COVID-19) pandemic.

Survival Disadvantages Persist Among Persons With HIV

June 15th 2020

Survival Disadvantages Persist Among Persons With HIV

Despite initiating antiretroviral therapy, overall and comorbidity-free–associated survival remain below that of the population without HIV.

Having COVID-19 May Not Increase Risk for Worse Outcomes Among Patients With HIV

June 12th 2020

Having COVID-19 May Not Increase Risk for Worse Outcomes Among Patients With HIV

Study results show a 4% mortality rate among HIV-positive patients who have coronavirus disease 2019 (COVID-19) compared with approximately 17% of patients who also have COVID-19 but are HIV-negative.

Prior Authorization for PrEP More Prominent in the South, May Represent Barrier to Care

June 10th 2020

Prior Authorization for PrEP More Prominent in the South, May Represent Barrier to Care

When used correctly, pre-exposure prophylaxis (PrEP) is effective more than 90% of the time, saving upward of $400,000 per averted HIV transmission.

Is There an Optimal Age at Which to Disclose HIV-Positive Status to Youth? Study Says Yes

June 5th 2020

Is There an Optimal Age at Which to Disclose HIV-Positive Status to Youth? Study Says Yes

Of the 1.8 million youth living with HIV around the world, the United States is home to 2000, and many were infected perinatally.

Possible Link Found Between Recent HIV Results, Testing-Related Behavior

June 3rd 2020

Possible Link Found Between Recent HIV Results, Testing-Related Behavior

There was a 6% increase from 2005 to 2014 in new HIV diagnoses among gay, bisexual, and other men who have sex with men, according to the CDC and study results published in Journal of Epidemiology and Community Health, and 1 in 6 is estimated to test positive for the disease at some point in his lifetime.

Does Gut Microbiota Influence Outcomes Among People With HIV?

May 29th 2020

Does Gut Microbiota Influence Outcomes Among People With HIV?

The life expectancy of a person living with HIV is approaching that of the general, seronegative population. However, changes to the bacterial environment of the intestinal tract combined with age-associated noncommunicable diseases can lead to chronic inflammation and higher rates of death.

Persons Living With HIV Have a Higher Risk of Recurrent Blood Clots

May 28th 2020

Persons Living With HIV Have a Higher Risk of Recurrent Blood Clots

Close to 40 million individuals are infected with HIV globally. A new study describes how some have a higher risk for a first venous thromboembolism that is 2 to 10 times above that of the general population.

How Does the Risk of HIV-1 Increase With Female Genital Schistosomiasis Infection?

May 22nd 2020

How Does the Risk of HIV-1 Increase With Female Genital Schistosomiasis Infection?

Schistosomiasis is the world’s second deadliest parasitic disease, and it can be linked to contaminated freshwater, with a majority of infections resulting from 3 types of bacteria: Schistosoma mansoni, S haematobium, or S japonicum. It is also a proposed factor for increasing the risk of HIV-1 infection in women.

Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts

May 21st 2020

Older Adults on ART Have Double the Mortality Risk of Their HIV-Negative Counterparts

Persons 50 years and older accounted for 3.6 million individuals living with HIV in 2013, and this number almost doubled to an estimated 6.7 million by 2017. Not all, however, are on antiretroviral therapy (ART).

Flexibility Is Key to Providing Ongoing Services to an HIV-Positive Population During the COVID-19 Pandemic

May 15th 2020

Flexibility Is Key to Providing Ongoing Services to an HIV-Positive Population During the COVID-19 Pandemic

Washington is home to 2 pertinent developments in the arrival of coronavirus disease 2019 (COVID-19) to the United States: the first US case of the virus was reported in the state on January 21 and the first major US city to report deaths as a result was Seattle.

Raltegravir-Based ART Regimens Appear Superior to Efavirenz for Use Among HIV-Positive Pregnant Patients

May 13th 2020

Raltegravir-Based ART Regimens Appear Superior to Efavirenz for Use Among HIV-Positive Pregnant Patients

Among the principal reasons for recommending initiating antiretroviral treatment (ART) among pregnant patients who are HIV positive is to prevent transmission of the virus to their unborn children. This number was estimated at 1.3 million pregnant women, as of 2018.

Sepsis Shown to Be Prevalent Among Patients With High HIV Viral Load

May 8th 2020

Sepsis Shown to Be Prevalent Among Patients With High HIV Viral Load

Close to 6 million individuals die every year as a direct result of sepsis infection, with a majority of these deaths occurring in low- and middle-income countries. The HIV-positive population in sub-Saharan Africa is disproportionately affected by this opportunistic infection.

May 5th 2020

STD Testing Rates, Service Receipt Among HIV-Positive MSM Remain Low

The CDC recommends regular testing for bacterial sexually transmitted diseases (STDs) among all sexually active gay, bisexual, and other men who have sex with men (MSM). Chief among these STDs are gonorrhea, chlamydia, syphilis, and hepatitis C.

Motivations, Attitudes Distinguish Consistent Versus Inconsistent ART Adherence

May 1st 2020

Motivations, Attitudes Distinguish Consistent Versus Inconsistent ART Adherence

According to 2015 CDC data, current viral suppression rates from antiretroviral therapy (ART) leave room for improvement among both HIV-positive individuals who are aware of their disease status and those receiving care, at 40.0% and 81.5%, respectively.

A Comprehensive Approach Is Best to Promote PrEP Use Among At-Risk Adolescents, CDC Says

April 29th 2020

A Comprehensive Approach Is Best to Promote PrEP Use Among At-Risk Adolescents, CDC Says

Preexposure prophylaxis (PrEP) was first approved by the FDA in 2012, but only for use among adults. An indication was added in 2018 for its use among adolescents.

Is Anti-CMV Treatment Necessary to Reduce CMV Viral Replication in Patients With HIV?

April 24th 2020

Is Anti-CMV Treatment Necessary to Reduce CMV Viral Replication in Patients With HIV?

Following interim results presented at the 2017 Conference on Retroviruses and Opportunistic Infections, a team of investigators from Vall d’Hebron in Spain delivered their final results at this year’s virtual conference on cytomegalovirus (CMV) viral load response to antiretroviral therapy compared with anti-CMV treatment.

Does an STI Diagnosis Spur Subsequent HIV Testing Among Adolescents?

April 20th 2020

Does an STI Diagnosis Spur Subsequent HIV Testing Among Adolescents?

Chlamydia, gonorrhea, syphilis, and trichomoniasis are 4 sexually transmitted infections (STI) that have seen sharp increases in occurrence over the past 10 years. Their combined overall rate rose 31% between 2013 and 2017 and correlate with a lower overall HIV testing rate among adolescents.

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

April 17th 2020

HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users

Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.

HIV Testing Rates, Frequency Leave Room for Improvement in Kenya

April 14th 2020

HIV Testing Rates, Frequency Leave Room for Improvement in Kenya

As of 2017, 184,718 young adult women and men were living with HIV in Kenya, for an annual prevalence of 2.61% and 1.34%, respectively. Female sex workers are at higher risk of contracting HIV.

Close to 100% of Active Duty Service Members Initiate ART and Achieve Viral Suppression, CDC Reports

April 9th 2020

Close to 100% of Active Duty Service Members Initiate ART and Achieve Viral Suppression, CDC Reports

Between 2012 and 2018, 93.8% of HIV-positive active military service members were on continuous antiretroviral therapy (ART). Of this group, 99.0% were virally suppressed by the end of their first year on ART.

HIV Disproportionately Affects Transgender Women, CDC Reports

April 7th 2020

HIV Disproportionately Affects Transgender Women, CDC Reports

Alison Rodriguez

There is a great need for additional outreach to the transgender community, especially by addressing concerns that include fear and loss of confidentiality, distrust of the medical community, abandonment, and abuse.

What Is the Risk of Cardiovascular Disease in Youth With HIV?

April 3rd 2020

What Is the Risk of Cardiovascular Disease in Youth With HIV?

Detectable viral load (VL) is associated with a significantly increased risk of cardiovascular disease (CVD) among US youth living with HIV, according to an abstract presented at the Conference on Retroviruses and Opportunistic Infections.

...

14 15 16 17 18 19 20 21 22

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions